TWST

Healthcare

Twist Bioscience Corporation · Medical - Diagnostics & Research · $4B

UQS Score — Balanced Preset
38.7
Below Average

Twist Bioscience Corporation scores 38.7/100 using the Balanced preset.

UQS vs Healthcare Sector
TWST
38.7
Sector avg
32.4
Quality
Weak
Moat
Weak
Growth
Strong
Risk
Good
Valuation
Elevated

What is Twist Bioscience Corporation?

Twist Bioscience is a synthetic biology company that manufactures DNA-based products using a proprietary silicon-chip writing platform. It is headquartered in South San Francisco, California.

Twist generates revenue by selling synthetic DNA products — including synthetic genes, antibody libraries, and sample-preparation tools — to researchers, drug developers, and data-storage innovators. The company also earns from collaboration agreements with pharmaceutical and genomics partners who use its platform to accelerate discovery work.

Twist Bioscience was incorporated in 2013 and is based in South San Francisco, California.

  • Synthetic genes and DNA fragments
  • Antibody libraries for drug discovery
  • NGS sample-preparation tools
  • DNA-based digital data storage solutions

Is TWST a Good Stock to Buy?

UQS Score rates TWST as Below Average overall.

The Growth and Risk pillars both register as Strong, reflecting meaningful top-line momentum and a risk profile that stands out relative to many early-stage biotech peers.

The Quality and Moat pillars are both Weak, and Valuation is Elevated — meaning investors may be paying a premium for a business that has yet to establish durable competitive advantages or consistent profitability.

See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →

Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.

Does TWST pay dividends?

No — Twist Bioscience Corporation does not currently pay a dividend.

Twist Bioscience does not currently pay a dividend. As an early-stage growth company, capital is directed toward expanding its DNA synthesis platform and funding research collaborations rather than returning cash to shareholders.

When does TWST report earnings?

Twist Bioscience reports earnings on a quarterly cadence, typical for US-listed equities.

Revenue growth has been a notable bright spot for Twist, consistent with its Strong Growth pillar rating. Profitability, however, remains a work in progress as the company continues to invest heavily in platform development and partnership expansion.

For the most recent quarter's results, visit Twist Bioscience's investor relations page directly.

TWST Price History

-41.7% over 5Y

Monthly close, adjusted for stock splits and dividend reinvestment.

Return Calculator

What if I invested in Twist Bioscience Corporation?

$
Today it would be worth
$4,947
That's a -50.5% total return, or -13.1% annualized.

Based on Twist Bioscience Corporation's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.

Frequently Asked Questions

What does Twist Bioscience do?

Twist Bioscience manufactures synthetic DNA products using a silicon-chip-based writing platform. Its offerings serve drug discovery, genomics research, and emerging DNA data-storage applications. The company also partners with pharmaceutical and clinical genetics organizations through collaboration agreements.

Does TWST pay dividends?

No, TWST does not pay a dividend. Twist Bioscience is focused on growth and reinvests available capital into platform expansion and research partnerships rather than shareholder distributions.

When does TWST report earnings?

Twist Bioscience follows a standard quarterly reporting cadence. For confirmed dates and the latest results, check the investor relations section of the company's official website.

Is TWST a good stock to buy?

UQS Score rates TWST as Below Average. While Growth and Risk pillars are Strong, the Weak Quality and Moat ratings alongside an Elevated Valuation suggest meaningful trade-offs. The complete pillar breakdown is available to Pro members at uqs-score.com.

Is TWST overvalued?

The UQS Valuation pillar for TWST is rated Elevated, indicating the market price may already reflect optimistic growth expectations. Investors should weigh this against the company's current profitability profile before drawing conclusions.

What is TWST's market cap bracket?

Twist Bioscience is classified as a mid-cap stock based on its current market capitalization.

Is TWST a long-term quality investment?

From a quality-indicator standpoint, TWST's Weak Quality and Moat pillars present challenges for long-term conviction. The Strong Growth pillar offers a counterbalance, but durable competitive advantages have not yet been clearly established according to the UQS framework.

What sector does TWST belong to?

Twist Bioscience operates in the Healthcare sector, specifically within synthetic biology — a field focused on engineering biological systems and manufacturing DNA-based tools for research, therapeutics, and data storage.

Unlock Full TWST Analysis

Sign in to unlock the detailed analysis behind the UQS Score.

  • View the exact UQS pillar scores across Quality, Growth, Moat, Risk, and Valuation
  • Access detailed financial metrics and trend data
  • Compare TWST against sector peers on a standardized scoring framework
  • Get the complete analyst view available only to Pro members
Analyze TWST in Detail →

Pro Analysis

TWST — Score History

3035404550Apr 2Apr 12Apr 22May 2May 12May 22May 24v5
Score changes· 2 most recent
DateUQSQualityMoatGrowthRiskValueChange
May 22, 202638.712.533.085.568.10.0-1.9
Apr 2, 202640.612.533.085.581.00.0

TWST — Pillar Breakdown

Quality

12.5/100 (25%)

Twist Bioscience Corporation currently shows below-average quality metrics, suggesting challenges with profitability.

Capital Efficiency (ROIC)Weak

How effectively capital is deployed to generate returns.

Return on EquityWeak

Profitability relative to shareholders' equity.

Operating ProfitabilityWeak

Ability to convert revenue into operating profit.

Net ProfitabilityWeak

Bottom-line profit as a share of revenue.

Gross Profit / AssetsStrong

Asset productivity — how much gross profit each dollar of assets generates.

Cash GenerationWeak

Free cash flow relative to market value.

Growth

85.5/100 (20%)

Twist Bioscience Corporation is growing rapidly with strong revenue and earnings expansion.

Recent Revenue TrendModerate

Revenue trajectory over the last twelve months.

3Y Revenue CAGRStrong

Compound annual revenue growth rate over 3 years.

EPS GrowthStrong

Year-over-year earnings per share growth.

Forward Revenue OutlookStrong

Analyst consensus for future revenue growth.

Risk

68.1/100 (15%)

Twist Bioscience Corporation maintains a reasonable risk profile with manageable debt levels.

Financial LeverageModerate

Debt levels relative to earnings capacity.

Debt/EquityStrong

Total debt relative to shareholder equity.

Current RatioStrong

Short-term liquidity — ability to pay near-term obligations.

Interest CoverageWeak

Earnings capacity relative to interest payments.

Valuation

0.0/100 (15%)

Twist Bioscience Corporation appears expensively valued relative to its fundamentals and growth prospects.

Moat

33/100 (25%)

Twist Bioscience Corporation operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for TWST.

Score Composition

Quality
12.5×25%3.1
Growth
85.5×20%17.1
Risk
68.1×15%10.2
Valuation
0.0×15%0.0
Moat
33.0×25%8.3
Total
38.7Below Average

Financial Data

More Stock Analysis

How is the TWST UQS Score Calculated?

The UQS (Unified Quality Score) for Twist Bioscience Corporation is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Twist Bioscience Corporation's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Twist Bioscience Corporation is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.